Cytomegalovirus pneumonia — a consequence of immunosuppression and pre-existing lung damage rather than immunopathology?  by Morris, D.J.
Respiratory Medicine (1993) 87,345-349 
Cytomegalovirus pneumonia - a consequence of 
immunosuppression and pre-existing lung damage 
rather than immunopathology? 
D. J. MORRIS 
Division of Virology, Department of Pathological Sciences, Medical School (Stopford Building), Oxford Road, 
Manchester Ml3 9PT. U.K. 
Introduction 
Cytomegalovirus pneumonia occurs in kidney, bone 
marrow, heart and heart-lung allograft recipients. 
(1,2), but its existence in patients with the acquired 
immune deficiency syndrome (AIDS) is debated (3). 
Ganciclovir, a drug with in vitro activity against 
human cytomegalovirus (CMV), has failed to reduce 
the mortality when given as treatment for this pneu- 
monia in bone marrow allograft recipients, despite a 
large reduction of virus titres in the lungs (4). This 
has led to a hypothesis that CMV pneumonia is an 
immunopathological condition (5). Not withstanding, 
clinical and laboratory observations emphasize the 
importance of immunosuppression and pre-existing 
lung damage as antecedents of this disease. Viraemia 
and virus invasion of the lungs precede the pneumonia. 
An alternative hypothesis for the pathogenesis of 
CMV pneumonia is therefore proposed. 
Clinical Observations 
Immunosuppression is a pre-requisite for the 
development of CMV pneumonia (1). Among organ 
allograft recipients in general the incidence of CMV 
pneumonia correlates with the degree of immuno- 
suppression. This incidence is increased in renal or 
bone marrow allograft recipients by administration 
of anti-thymocyte globulin (ATG) (6,7). CMV pneu- 
monia is rare in renal patients given maintenance 
prednisolone only sparingly (8), and it may resolve 
following withdrawal of immunosuppression (9). 
Among bone marrow allograft recipients, factors 
associated with an increased risk of CMV pneumonia 
include pre-transplant conditioning with ATG or 
total body irradiation (TBI) in patients with aplastic 
anaemia (1,7), pre-transplant conditioning with the 
cytotoxic drug bichloroethylnitrosourea in patients 
with haematological malignancy (l), and post- 
transplant moderate to severe acute graft-versus-host 
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disease (GVHD) (7). The incidence of all interstitial 
pneumonias [and perhaps of CMV pneumonias which 
comprise approximately 40% of interstitial pneu- 
monias (7)] is increased by conditioning for marrow 
allografting using dose rates of TBI exceeding 0.04 
0.06 Gy min.’ when methotrexate provides prophy- 
laxis against GVHD (10,ll). Doses of TBI greater 
than 6 Gy may also be associated with an increased 
risk of CMV pneumonia (12), though two studies have 
failed to document a link between the irradiation dose 
and the risk of all interstitial pneumonias (10,ll). The 
importance of acute GVHD as a risk factor for CMV 
pneumonia in marrow allograft recipients is empha- 
sized by the absence of both conditions in recipients of 
syngeneic grafts (13). 
Laboratory Observations 
Natural killer (non-T) and T-cell cytotoxic effector 
responses are an important component of the cellular 
immune response in the context of acquisition of and 
recovery from CMV infection in allograft receipients 
(14). Most currently available data relate to cytotoxic 
cell responses in the peripheral blood. The develop- 
ment of CMV-specific cytotoxic responses during 
infection correlates with a decreased likelihood of 
pneumonia and death in marrow allograft recipients, 
and a decreased likelihood of death in renal allograft 
recipients. Natural killer cell activity against CMV- 
infected cells is depressed in renal allograft recipients 
for the first 2 yr after transplantation, but rises to 
high levels following reductions in immunosuppress- 
ive therapy and in temporal association with resol- 
ution of CMV disease. In marrow allograft recipients, 
retention of natural cytotoxic activity against virus- 
infected target cells is associated with longer survival 
after CMV infection, and depression of such cytotoxic 
activity relative to normal controls accompanies the 
onset of acute GVHD. Depression of CMV-specific 
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cytotoxic T-cell responses in renal and bone marrow 
allograft recipients may follow high-dose methyl- 
prednisolone therapy, as in the former patients these 
responses are largely abolished 5-14 days after 
therapy, and in the latter patients the use of methyl- 
prednisolone and not merely the presence of GVHD 
correlates with reduced T-cell responses. 
Natural killer cells mediating cytotoxic activity 
directed against virus-infected cells have been detected 
in bronchoalveolar lavage fluid collected from patients 
with CMV pneumonia (15). This cytotoxic activity was 
greater than that detected in the patients’ peripheral 
blood, but its magnitude did not vary with the out- 
come of the pneumonia in the smaller number of 
patients studied (15). 
CMV pneumonia and interstitial pneumonia associ- 
ated with ionizing radiation or administration of cyto- 
toxic drugs such as bichloroethylnitrosourea share 
several pathological features, including proliferation 
and desquamation of pneumocytes, accumulation of 
alveolar exudate, alveolar haemorrhage, fibrin depo- 
sition, interstitial edema, and formation of hyaline 
membranes (16-20). Functional damage to alveolar 
walls, perhaps in particular to pneumocytes, may be 
central to the pathogenesis of both CMV and inter- 
stitial pneumonias, in that reduction of the carbon 
monoxide diffusion capacity is almost always present 
(1,16). CMV probably replicates in pneumocytes as 
typical viral inclusions are present in these cells in 
patients with CMV pneumonia (18). CMV replication 
ultimately switches off host cell macromolecular syn- 
thesis (21) and this effect may underlie the functional 
damage to pneumocytes in the pneumonia. These 
observations suggest that pre-existing lung damage 
produced by irradiation or cytotoxic drugs could 
exacerbate lung damage consequent on pulmonary 
CMV infection. 
Patients with CMV pneumonia have a high preva- 
lence of preceding CMV viraemia (1,2,6). The reported 
failure to document viraemia in all patients with this 
pneumonia (7) may reflect the reduced sensitivity of 
virus isolation when blood samples are anticoagulated 
with heparin rather than Alsever’s or citrate solution 
(22) and when leucocytes are separated by sedimen- 
tation rather than by density-gradient centrifugation 
(23). Subclinical pulmonary infection probably pre- 
cedes overt pneumonia. Detection of virus in broncho- 
alveolar lavage fluid in asymptomatic bone marrow 
allograft recipients correlates with the subsequent 
development of pneumonia (24). Moreover, alveolar 
wall dysfunction manifest as a reduced carbon mon- 
oxide diffusion capacity is a virtually constant accom- 
paniment of CMV infection in immunosuppressed 
renal transplant patients (25). 
Proposed Pathogenesis of CMV Pneumonia 
CMV reaches the lungs during an episode of 
viraemia. Two steps occur between the onset of 
viraemia and the onset of clinically apparent pneu- 
monia. First, virus invasion of the lung parenchyma, 
in the form of infection of occasional pneumocytes, 
produces subclinical pulmonary infection manifest 
as virus shedding in bronchoalveolar secretions and 
perhaps resulting in an alveolar diffusion deficit. 
Second, virus replication and dissemination in the 
lung, mainly in pneumocytes, leads to clinically 
and radiologically apparent pneumonia. Functional 
damage to or destruction of pneumocytes is central to 
the development of CMV pneumonia, and reflects 
either the direct effects of infection of these cells on 
host cell macromolecular synthesis or their immune 
destruction by cytotoxic cells. 
Immunosuppression promotes the development of 
CMV pneumonia by increasing the likelihood that 
viraemia will lead to pneumonia. The effects of immu- 
nosuppression and acute GVHD on the risk of this 
pneumonia are mediated by depression of specific 
cytotoxic T and non-T cell responses. Depression of 
these responses predisposes to the development of 
pneumonia by increasing the likelihood of either virus 
infection or of dissemination within the lung. The high 
prevalence of subclinical pneumonia in CMV-infected 
renal transplant patients who escape clinical pneu- 
monia suggests that the second mechanism is the more 
important. 
Radiotherapy and cytotoxic chemotherapy increase 
the risk of CMV pneumonia in immunosuppressed 
patients by reducing the extent of virus-induced 
damage of pneumocytes required to produce clinically 
overt pneumonia. The shared pulmonary pathological 
effects of CMV, irradiation, and cytotoxic drugs act 
additively or perhaps even synergistically; the effects of 
each factor in isolation produce only subclinical pneu- 
monia, but acting together they may induce clinically 
apparent pneumonia. 
Resolution of CMV pneumonia probably depends 
on the development of systemic and local virus-specific 
cytotoxic cell responses, though the magnitude of 
these pulmonary responses has not yet been shown to 
correlate with the likelihood of recovery. Withdrawal 
of iatrogenic immunosuppression facilitates resol- 
ution of the pneumonia by allowing cytotoxic cell 
responses to develop. The failure of antiviral chemo- 
therapy to ameliorate CMV pneumonia in bone mar- 
row allograft recipients reflects late treatment of the 
disease at a stage when irreversible lung damage has 
already occurred. Eradication of virus from the lung 
at this stage achieves little benefit. Pre-existing lung 
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damage induced by irradiation or cytotoxic drugs 
means that irreversible lung damage occurs earlier in 
the evolution of CMV pneumonia. 
Role of Immunopathology 
Grundy et al. propose that CMV pneumonia 
develops as a consequence of immunopathological 
damage to the lung parenchyma (5). This damage is 
supposedly mediated by T-cell reactivity directed 
against cells expressing viral antigens. Evidence cited 
in support of this hypothesis comprises the putative 
efficacy of CMV immune globulin in the treatment of 
CMV pneumonia, and the apparently immunopatho- 
logical basis of pneumonia produced by murine 
cytomegalovirus (MCMV) in mice. Grundy and co- 
workers postulate that specific immune therapy pro- 
motes resolution of CMV pneumonia in man because 
antibody binds to viral or other antigens expressed 
on cells in the lung, thus blocking T-cell-mediated 
immune damage. There is however, no evidence to 
support this mechanism of action. Indeed, the thera- 
peutic efficacy of immune globulin alone or in combi- 
nation with ganciclovir remains unproven in CMV 
pneumonia (26,27). 
The hypothesis that MCMV pneumonia is a T-cell- 
dependent immunopathological condition rests on 
the ability of GVHD to promote its development, the 
prophylactic efficacy of continuous therapy with 
the immunosuppressive drug cyclophosphamide, and 
the absence of the pneumonia in infected T-cell- 
deficient athymic nude mice (5). Also, the titre of virus 
in the lungs correlates poorly with the development of 
pneumonia, and inhibition of intra-pulmonary virus 
replication by ganciclovir does not prevent pneumonia 
(5). Nonetheless, a role for T-cell-mediated immuno- 
pathology in the pathogenesis of MCMV pneumonia 
cannot be taken of itself to imply a similar pathogen- 
esis for CMV pneumonia in man. The two diseases are 
caused by different viruses invading different hosts, 
and at least some of the apparently immunopatho- 
logical characteristics of MCMV pneumonia are not 
found in human CMV pneumonia. Continuous ther- 
apy with the immunosuppressive drugs cyclosporin 
and prednisolone does not prevent CMV pneumonia 
in renal, heart, or heart-lung transplant recipients 
(2,28), and high-dose methylprednisolone therapy is 
not effective when given with ganciclovir to bone 
marrow allograft recipients with this disease (4). CMV 
pneumonia occurs in patients given T-cell-depleted 
bone marrow allografts (29). The apparent absence of 
reports of severe CMV pneumonia in T-cell-deficient 
infants with DiGeorge syndrome (30) may reflect the 
extreme rarity of this syndrome rather than an involve- 
ment of T-cell-dependent immunopathological events 
in the pathogenesis of CMV pneumonia. The associ- 
ation between CMV pneumonia and acute GVHD in 
marrow graft patients can be explained by depression 
of cytotoxic cell responses following prednisolone 
therapy given for GVHD (see above) rather than by 
promotion of immunopathological events. 
Implications 
Interaction between pre-existing lung damage and 
the degree of immunosuppression in the pathogenesis 
of CMV pneumonia may explain the greater incidence 
of this disease in recipients of heart-lung rather than 
heart allografts, and its rarity in patients with AIDS. 
Transplant patients given heart-lung rather than heart 
grafts receive more intensive immunosuppressive ther- 
apy and develop more lung damage because of pul- 
monary allograft rejection (2) and patients with AIDS 
are unlikely to have pre-existing lung damage at least 
in the early stages of the disease. Thus an immuno- 
pathological pathogenesis for CMV pneumonia is not 
essential to explain the apparent rarity of CMV pneu- 
monia in patients with AIDS (3). If previous lung 
damage promotes the development of CMV pneu- 
monia, one might predict an increasing risk of CMV 
pneumonia in patients with AIDS later in the disease 
after multiple episodes of Pneumocystis carinii or other 
pneumonias. 
The proposed pathogenesis for CMV pneumonia 
suggests two possible strategies by which this pneu- 
monia might be prevented and its mortality reduced: 
first, by minimizing iatrogenic immunosuppression, 
and second, by avoiding factors which promote lung 
damage. The effectiveness of the first strategy is indi- 
cated by the rarity of the disease in cyclosporin-treated 
renal allograft recipients given no or only minimal 
doses of maintenance prednisolone (8). Its low inci- 
dence in bone marrow allograft recipients conditioned 
with low dose rates of TBI possibly indicates the effec- 
tiveness of avoiding pulmonary toxins (3 1). However, 
use of cyclosporin, an agent associated with a low 
incidence of GVHD (31) may also be important if 
excessive iatrogenic immunosuppressive is thereby 
avoided. As death from CMV pneumonia is a major 
determinant of the outcome of allogenic marrow graft- 
ing (17) application of the above preventative strat- 
egies could be vital in improving the success of this 
transplantation procedure. 
Currently, the most promising strategy for the 
control of CMV pneumonia in bone marrow trans- 
plant recipients is early administration of chemo- 
prophylaxis to patients with pulmonary infection 
detectable in bronchoalveolar lavage fluid (32). In a 
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recently reported placebo-controlled trial, ganciclovir 12. 
significantly reduced the incidence of subsequent 
CMV pneumonia in such patients. The haematologi- 13. 
cal toxicity of ganciclovir (4) nonetheless probably 
precludes its similar use in renal transport patients who 
have only a low incidence of CMV pneumonia (8). 14. 
The hypothesis that pre-existing lung damage 
hastens the onset of irreversible lung damage in 
patients with CMV pneumonia predicts that antiviral 
chemotherapy is more likely to be successful if it is 15. 
given early in the disease or if pre-existing lung damage 
is absent. There is some evidence which supports this 
prediction (4). However, successful treatment of CMV 
pneumonia may only be possible when less toxic anti- 16. 
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